Short answer
ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on October 19, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Publication of Phase 1b FURTHER trial results for firmonertinib in Cancer Cell.
ArriVent BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Publication of Phase 1b FURTHER trial results for firmonertinib in Cancer Cell
- Results concern FURMO-002, clinical trial NCT05364073
- Peer-reviewed publication may support firmonertinib’s clinical credibility and investor assessment of development prospects
Item EX-99.1 · Exhibit EX-99.1
- Cancer Cell publication strengthens firmonertinib’s clinical and mechanistic case in underserved EGFR PACC-mutant NSCLC
- Front-line confirmed ORR reached 43% at 160 mg and 68% at 240 mg, with median PFS of 11.1 and 16.0 months
- Intracranial ORR was 47% in patients with baseline brain metastases, including 41% complete responses
- Phase 3 ALPACCA trial underway against investigator-choice osimertinib or afatinib, creating a key regulatory and valuation catalyst
- ctDNA clearance by cycle 3 correlated with ORR of 70% versus 20% and median PFS of 15.1 versus 3.0 months
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ArriVent BioPharma, Inc. 8-K filings
Get the next AVBP 8-K as it lands
Follow AVBP for push alerts, or ask the research agent what this filing means.